Nanophthalmos: A Review of the Clinical Spectrum and Genetics

Pedro Carlos Carricondo, Thais de Souza Andrade, Lev Prasov, Bernadete Ayres, Sayoko E. MoroiJournal of Ophthalmology 2018 · DOI

TL;DR

This review synthesizes current knowledge on nanophthalmos, a condition characterized by abnormally small but structurally normal eyes. It highlights the significant clinical challenges, particularly the high risk of secondary glaucoma and surgical complications, and details the genetic underpinnings of this disorder, identifying key genes and pathways involved.

What Problem Does This Paper Address?

The paper addresses the complex and often challenging clinical presentation of nanophthalmos. This condition, defined by a small eye with otherwise normal structures, poses significant difficulties for ophthalmologists due to its association with secondary angle-closure glaucoma, spontaneous choroidal effusions, and increased risks during cataract and retinal surgeries. Understanding the full clinical spectrum and the genetic basis of nanophthalmos is crucial for accurate diagnosis, effective management, and the development of targeted therapies. The paper aims to consolidate this information, providing a comprehensive overview for researchers and clinicians.

Methods

This review is based on a comprehensive literature search of Medline/PubMed using keywords such as "nanophthalmos," "ocular development," and "genetics." Studies published in English, Portuguese, or Spanish up to December 2017 were included. The authors also reviewed the references of selected articles to ensure a thorough compilation of relevant research. Patient images were obtained with appropriate consent.

Datasets

Not discussed in the paper. The paper is a review article and does not present new experimental data or datasets.

Key Insights and Ideas

  • Nanophthalmos as a Spectrum: The paper emphasizes that nanophthalmos is not a single entity but a spectrum of disorders characterized by a small eye, often with a continuum of axial length reduction and anterior segment features.
  • High Risk of Complications: A critical takeaway is the significantly elevated risk of secondary angle-closure glaucoma, spontaneous choroidal effusions, and intraoperative complications during eye surgeries in nanophthalmic eyes.
  • Genetic Heterogeneity: Nanophthalmos has a strong genetic basis, with mutations identified in several genes (MFRP, TMEM98, PRSS56, BEST1, CRB1) and associated with specific chromosomal loci, indicating diverse underlying molecular mechanisms.
  • MFRP's Central Role: The MFRP gene is highlighted as a key player, with mutations linked to recessive nanophthalmos and a broad spectrum of ocular phenotypes, including retinitis pigmentosa and optic disc drusen.
  • Potential for Gene Therapy: Promising research using gene therapy in mouse models of MFRP deficiency suggests a potential future avenue for treating nanophthalmos.
  • Distinguishing from Posterior Microphthalmos: The paper discusses the ongoing debate and clinical distinctions between nanophthalmos and posterior microphthalmos, suggesting they might represent points on a continuum rather than entirely separate conditions.

Key Results

The review consolidates findings from numerous studies, highlighting:

  • Clinical Features: Nanophthalmic eyes are characterized by high hyperopia (often +8.00 D to +25.00 D or higher), shallow anterior chambers, thickened choroid and sclera, and reduced axial length (typically <21 mm).
  • Genetic Links: Five genes (MFRP, TMEM98, PRSS56, BEST1, CRB1) and two loci have been implicated in familial forms of nanophthalmos, with mutations leading to autosomal-dominant or recessive inheritance patterns.
  • Complication Rates: The incidence of angle-closure glaucoma in nanophthalmic eyes can be as high as 69.23%, and intraoperative complication rates during surgery range from approximately 40-60%.
  • Gene Therapy Success: In Mfrp deficient mouse models, subretinal injection of a vector carrying a normal Mfrp gene successfully rescued photoreceptor death, normalized retinal function, and regulated eye length.

Limitations and Future Work

  • Limitations: The paper acknowledges that the precise role of some genes (e.g., TMEM98) in nanophthalmos pathogenesis is still being elucidated. The distinction between nanophthalmos and posterior microphthalmos remains a subject of debate, with varying definitions and clinical observations. The genetic background and environmental modifiers contributing to clinical variability in MFRP-related conditions are not fully understood.
  • Future Work: The authors suggest that further research is needed to fully understand the specific roles of identified genes and to explore potential genetic modifiers. The success of gene therapy in animal models points towards this as a promising future direction for treatment. Genetic diagnoses are expected to improve genetic counseling, facilitate early detection, and potentially lead to novel therapeutic strategies for nanophthalmos.

Summary updated

Abstract

Nanophthalmos is a clinical spectrum of disorders with a phenotypically small but structurally normal eye. These disorders present significant clinical challenges to ophthalmologists due to a high rate of secondary angle-closure glaucoma, spontaneous choroidal effusions, and perioperative complications with cataract and retinal surgeries. Nanophthalmos may present as a sporadic or familial disorder, with autosomal-dominant or recessive inheritance. To date, five genes (i.e., <i>MFRP</i>, <i>TMEM98</i>, <i>PRSS56</i>, <i>BEST1</i>, and <i>CRB1</i>) and two loci have been implicated in familial forms of nanophthalmos. Here, we review the definition of nanophthalmos, the clinical and pathogenic features of the condition, and the genetics of this disorder.
BibTeX
@article{carricondo2018nanophthalmos,
  author = {Pedro Carlos Carricondo and Thais de Souza Andrade and Lev Prasov and Bernadete Ayres and Sayoko E. Moroi},
  title = {{Nanophthalmos: A Review of the Clinical Spectrum and Genetics}},
  journal = {Journal of Ophthalmology},
  year = {2018},
  doi = {10.1155/2018/2735465},
}
Figure